Is there a role for MRD monitoring in the decision to switch from a triplet regimen to maintenance therapy in transplant-ineligible myeloma patients?  

There is no role for MRD monitoring in the decision to switch from 3-drug therapy to maintenance, yet. First, MRD status is not the only variable to consider. It's ideal to personalize ongoing therapy as high-risk myeloma may require 3-drug therapy to remain in control, and low-risk disease may stay...